14:06 , Mar 18, 2019 |  BC Extra  |  Financial News

Karuna looks past schizophrenia with $68M series B

Karuna intends to execute on its broader ambitions for lead program KarXT xanomeline/trospium chloride beyond schizophrenia, including development in at least two new indications, after raising $68 million in series B funding. By late 2019,...
20:23 , Oct 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Addiction Rat studies suggest M1 muscarinic receptor (CHRM1)-based chemogenetic inhibition of the prelimbic paraventricular thalamic nucleus pathway could help treat cocaine addiction. The system for chemogenetically inhibiting the pathway is initiated by bilateral injection...
17:33 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest antagonizing the muscarinic receptor CHRM1 could help treat white matter injury. In a mouse model of neonatal chronic hypoxia-induced white matter injury, CHRM1 knockout in oligodendrocyte precursor cells increased axon...
17:38 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Sosei, Allergan to delay trials of dementia candidate

Sosei Group Corp. (Tokyo:4565) and partner Allergan plc (NYSE:AGN) have suspended clinical development of neurodegenerative candidate HTL0018318 to investigate a toxicity signal -- a rare tumor -- found in a non-human primate treated with the...
22:24 , Sep 18, 2018 |  BC Extra  |  Clinical News

Sosei, Allergan to delay trials of dementia candidate

Sosei Group Corp. (Tokyo:4565) and partner Allergan plc (NYSE:AGN) have suspended clinical development of neurodegenerative candidate HTL0018318 to investigate a toxicity signal -- a rare tumor -- found in a non-human primate treated with the...
01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
20:43 , Aug 3, 2018 |  BioCentury  |  Finance

Karuna’s CNS double play

With $42 million in series A funding, Karuna Pharmaceuticals Inc. hopes its combination of muscarinic receptor-targeting therapies can lead to clinical benefits in CNS disorders without the peripheral side effects seen in previous studies. Along...
17:40 , Aug 3, 2018 |  BC Week In Review  |  Financial News

Karuna raises $42M series A

Karuna Pharmaceuticals Inc. (Boston, Mass.) raised $42 million in a series A round from Arch Venture Partners, the Wellcome Trust, Steven Paul, PureTech Health plc (LSE:PRTC) and other undisclosed investors. Karuna's lead product is KarXT...
18:23 , Aug 2, 2018 |  BC Extra  |  Financial News

Karuna raises $42M series A

Karuna Pharmaceuticals Inc. (Boston, Mass.) raised $42 million in a series A round from Arch Venture Partners, the Wellcome Trust, Steven Paul, PureTech Health plc (LSE:PRTC) and other undisclosed investors. Karuna's lead product is KarXT...
20:49 , Apr 6, 2018 |  BC Week In Review  |  Company News

Dermavant acquires compound from TheraVida

The Dermavant Sciences dermatology subsidiary of Roivant Sciences GmbH (Basel, Switzerland) in-licensed from TheraVida Inc. (San Mateo, Calif.) rights to develop and commercialize hyperhidrosis candidate RVT-504 (formerly THVD-102). TheraVida will receive an upfront payment and...